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P U B L I S H E D B Y E L S E V I E R I N C .LettersSame-Day Discharge and
Risks of Mortality and
Readmission After
Elective ICD Placement for
Primary PreventionMore than 100,000 patients annually receive an
implantable cardioverter-deﬁbrillator (ICD) in the
United States. Placement techniques for ICDs have
evolved and become safer, and hospital length of stay
has declined accordingly. Patients who receive an ICD
electively now are routinely discharged the next day.
Beneﬁts of shorter length of stay after ICD place-
ment include patient convenience, increased bed
availability, and the potential for lower costs. How-
ever, early discharge may accentuate the impact
of known complications, including mechanical com-
plications requiring system revision, hemothorax
or pneumothorax, cardiac perforation, infection,
bleeding, and death. Evaluation of same-day discharge
after ICD placement has been limited to small, single-
center studies in select patients (1,2). Using the
National Cardiovascular Data Registry’s ICD Registry
linked with Medicare claims, we assessed the preva-
lence of same-day discharge among older patients af-
ter elective ICD placement in the United States;
variation in discharge strategy over time and across
hospitals; and associations with death, all-cause
readmission, and device-speciﬁc readmission.
We included patients $65 years of age who had a
registry record for an ICD implantation between April
1, 2006, and December 31, 2009; those who were
enrolled in fee-for-service Medicare at the time of
the procedure; and those who could be linked to
Medicare claims data (n ¼ 206,611). We excluded
those patients who had a prior ICD implantation
(n ¼ 60,667); underwent implantation for secondary
prevention, including sustained ventricular tachy-
cardia (n ¼ 30,589); had New York Heart Association
functional class IV symptoms (n ¼ 4,835); were
admitted for a reason other than ICD implantation
(n ¼ 32,880); died in the hospital during the index
admission (n ¼ 91); were discharged to a facility other
than home (n ¼ 4,651); or had a hospital length of stay>1 day (n ¼ 14,703). We deﬁned same-day discharge
on the basis of an admission date equal to the
discharge date on the Medicare inpatient or outpa-
tient claim. Overnight observation was based on a
discharge date 1 day after the admission date on the
claim. We determined all-cause death from death
dates in the Medicare denominator ﬁles. Readmission
outcomes were based on subsequent inpatient claims.
We used Kaplan-Meier methods to estimate death
and log-rank tests to assess differences in death
between groups. We used the cumulative incidence
function for other outcomes and Gray tests to assess
differences in outcomes between the groups. We
used Cox proportional hazards models with robust
standard errors for hospital clustering to examine
univariate and multivariable associations between
same-day discharge and outcomes.
The ﬁnal study sample consisted of 58,195 patients
from 1,314 sites; 3,083 (5.3%) were discharged on
the same day as the ICD placement. Compared
with patients who were observed overnight, those
who were discharged the day after the procedure
were less frequently under the care of physicians
trained in electrophysiology or thoracic surgery and
more commonly underwent device implantation in
private-practice hospitals rather than government or
academic centers. Hospitals performing same-day
discharges were less often located in rural areas and
more commonly suburban areas. Rates of same-day
discharge varied by hospital, from 0% in 846 hospi-
tals (64%) to $50% in 27 hospitals (2%; interquartile
range 0.0% to 3.0%; range 0.0% to 100%). The overall
rate increased from 4.1% in 2006 to 6.6% in 2009.
Table 1 shows the observed cumulative incidence
of death, all-cause readmission, and device-related
readmission among patients with same-day dis-
charge and those observed overnight, as well as as-
sociations with study outcomes according to the
number of days after discharge. There were no sig-
niﬁcant differences in observed rates between the
groups. After multivariable adjustment, same-day
discharge was not signiﬁcantly associated with
death, all-cause readmission, or device-related read-
mission 90 days after discharge.
Practitioners routinely perform a physical exa-
mination, obtain a chest x-ray, and perform device
interrogation the day after an elective procedure
TABLE 1 Outcomes Between Same-Day Discharge and Overnight Observation
Outcome
Observed Cumulative Incidence
Unadjusted Association
Same Day Versus Overnight
Adjusted Association
Same Day Versus Overnight*
Same-Day
Discharge
(n ¼ 3,083)
Overnight
Observation
(n ¼ 55,112) p Value
Hazard Ratio
(95% CI) p Value
Hazard Ratio
(95% CI) p Value
Death
7 days <11 (<0.4)† 56 (0.1) 0.08 —‡ —‡ —‡ —‡
30 days <11 (<0.4)† 178 (0.3) 0.36 —‡ —‡ —‡ —‡
90 days 33 (1.1) 694 (1.3) 0.36 0.85 (0.61–1.18) 0.33 0.86 (0.61–1.23) 0.41
All-cause readmission
7 days 93 (3.0) 1386 (2.5) 0.08 1.20 (0.95–1.52) 0.12 1.33 (1.06–1.69) 0.02
30 days 243 (7.9) 4398 (8.0) 0.88 0.99 (0.86–1.14) 0.88 1.06 (0.92–1.23) 0.40
90 days 511 (16.7) 9473 (17.3) 0.42 0.96 (0.88–1.06) 0.45 1.02 (0.92–1.12) 0.73
Device-related readmission
7 days 16 (0.5) 254 (0.5) 0.64 —‡ —‡ —‡ —‡
30 days 38 (1.2) 748 (1.4) 0.56 0.91 (0.65–1.27) 0.57 1.01 (0.72–1.41) 0.95
90 days 57 (1.9) 1318 (2.4) 0.05 0.77 (0.58–1.03) 0.08 0.85 (0.64–1.13) 0.26
Values are n (%) unless otherwise indicated. *Adjusted for age, sex, race, atrial ﬁbrillation, nonsustained ventricular tachycardia, abnormal sinus node function, nonischemic
dilated cardiomyopathy, ischemic heart disease, prior myocardial infarction, prior coronary artery bypass grafting, prior percutaneous intervention, prior valvular surgery, prior
pacemaker implantation, cerebrovascular disease, chronic lung disease, diabetes, hypertension, renal failure, New York Heart Association functional class, ejection fraction, QRS
duration, intraventricular conduction delay, left bundle-branch block, atrioventricular conduction, type of implantable cardioverter-deﬁbrillator (ICD), systolic blood pressure,
serum sodium, serum creatinine, blood urea nitrogen level, prescription of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker at discharge, prescription of
b-blocker at discharge, prescription of warfarin at discharge, year of procedure, hospital proﬁt type, whether the implanting physician had adult electrophysiology training,
quartile of annualized physician ICD volume, and procedural complications. †In accordance with the privacy policy of the Centers for Medicare & Medicaid Services, data for cells
containing 10 or fewer observations are not reported. ‡Insufﬁcient events for calculation of hazard ratios.
CI ¼ conﬁdence interval.
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956and prior to patient discharge. For appropriate pa-
tients, a new practice model may incorporate novel
care processes but not require overnight observation,
particularly if the patient undergoes ICD placement
early in the day. These care processes include moni-
toring for several hours after the procedure while the
patient recovers from sedation, follow-up chest x-ray
and device interrogation, effective communication
regarding wound care, and arrangement of close
outpatient follow-up.
A number of ICD recipients presently monitored
overnight may undergo same-day discharge with
appropriate follow-up without increased risk of
adverse events. In fact, patients who undergo ICD
placement late in the day followed by discharge the
next morning may receive a comparable level of care.
Centers considering implementation of same-day
discharge may beneﬁt from developing protocols
to identify eligible patients, monitor them adequately
after the procedure, and arrange close outpatient
follow-up. Same-day discharge is not suitable for all
patients, because some patients are at sufﬁciently
high risk to warrant observation for longer periods.
Patients who undergo cardiac resynchronization
therapy often have advanced heart failure and sig-
niﬁcant comorbidity and may require close moni-
toring. Patients with known procedural complications
also may beneﬁt from a longer observation period.
Standardized criteria for same-day dischargedeveloped by professional societies or hospitals
would be valuable. In the absence of such criteria,
discharge strategy should be carefully selected on a
patient-by-patient basis by the treating physician.
Similar to same-day discharge after percutaneous
coronary intervention, same-day discharge after ICD
placement may lead to greater patient satisfaction,
increased bed availability for patients with greater
clinical need, and cost savings without adversely
affecting readmission rates (3). Rates of readmission
are particularly relevant, as they are already consid-
ered a quality metric for disease states such as heart
failure and may be bundled to reimbursement for the
index hospitalization in the future. Discharge policy
changes may be implemented in select patients
without adversely affecting readmission rates and
in turn public perception regarding quality of care
or reimbursement. New healthcare models should
consider the value and outcomes of same-day dis-
charge for appropriate patients.Paul L. Hess, MD
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Continued-Warfarin
Versus Heparin-Bridging
Therapy During Pacemaker
and Deﬁbrillator SurgeryIn patients receiving warfarin due to high risk of
thromboembolic events, current guidelines recom-
mend bridging therapy with heparin or low molec-
ular weight heparin (LMWH) during surgery for
cardiac pacemakers or implantable cardioverter-
deﬁbrillators (1). Bridging therapy is associated
with increased costs due to increased need for hos-
pitalization and the high price of LMWH (2). The
recent randomized controlled BRUISE CONTROL
(Bridge or Continue Coumadin for Device Surgery
Randomized Controlled Trial; NCT00800137) of 681
patients undergoing nonemergency device surgery
found that patients receiving continued-warfarintherapy experienced signiﬁcantly fewer clinically
signiﬁcant hematomas than those receiving heparin-
bridging therapy (3). In this economic evaluation,
we compared treatment with warfarin to bridging
therapy with heparin.
From the perspective of the Canadian health-
care system, this study sought to assess the cost
effectiveness of continued-warfarin versus heparin-
bridging therapy in pacemaker or deﬁbrillator
surgery using data from the recent single-blind ran-
domized controlled trial (4). We collected resource
use for the initial hospitalization, including antico-
agulant usage, hospitalization for intravenous hepa-
rin administration (17% of heparin-bridging arm),
laboratory tests, and extensions of hospitalization
due to complications; and at ﬁnal follow-up to assess
repeat hospitalizations, emergency room visits, and
management of complications. Appropriate Canadian
unit costs were obtained for all resource use collected
and estimated for 2012 to 2013 (5). The primary
outcome measure was the incremental cost or cost
savings per hematoma avoided with appropriate
assessment of the uncertainty around the estimates of
costs, outcomes, and incremental cost-effectiveness
ratios (4). The effect of a range of factors on the
costs within the 2 treatment arms was explored
through sensitivity analyses.
The overall cost of continued-warfarin therapy was
dramatically lower than heparin-bridging therapy
($218 vs. $2,041; p < 0.001), primarily due to lower
costs for medication ($11.57  $0.64 vs. $353.91 
$15.09) and hospitalizations ($41.72  $37.81 vs.
$1,114.60  $164.90). There were more clinically
signiﬁcant hematomas within the bridging-heparin
group compared with continued-warfarin group
(54 vs. 12, respectively), resulting in a trend for
increased hematoma costs per patient in the heparin-
bridging group ($511.89  $199.26 vs. $118.89 
$69.50; p ¼ 0.060).
Continued-warfarin therapy had fewer clinically
signiﬁcant hematomas compared with heparin-
bridging therapy (3.6% vs. 16.6%; p < 0.001). As
continued-warfarin therapy was also less costly, it
was dominant. In all replications of the non-
parametric bootstrap, continued-warfarin therapy
remained dominant indicating little uncertainty
in the results. Continued-warfarin therapy remained
the dominant treatment strategy in all analyses
(Table 1).
In conclusion, continued-warfarin therapy was
found to be cost effective compared with bridging-
heparin therapy in patients at high risk of throm-
boembolic events undergoing device surgery, with a
cost savings of approximately $1,800 per patient
